latest news releases from the newsroom
Shazamstocks.com Announces Profile Launch of m-Wise, Inc.
GRANGER, Ind., March 28, 2005 (PRIMEZONE) -- Ken Weiner, Publisher of Shazamstocks.com, today announced profile coverage of m-Wise, Inc. (OTCBB:MWIS). The profile is a comprehensive look at the company's growth imitative. You can view the complete profile at http://profiles.shaazamstocks.com/mwis/index.htm
Stock Research for the Nasdaq 100, eBay, Select Sector SPDR Energy and Brocade Communications from StockPickReport
SHREVEPORT, La., March 28, 2005 (PRIMEZONE) -- The following is an investment opinion issued by StockPickReport: StockPickReport.Com (IARD #119079, http://www.stockpickreport.com -- the web's only non-mainstream stock rating service), rates Nasdaq 100, eBay, Select Sector SPDR-Energy, Brocade Communications Systems Inc.
FTS Wireless, Inc.
FTS Breaks Monthly and Quarterly Sales Record
TAMPA, Fla., March 28, 2005 (PRIMEZONE) -- FTS Wireless, Inc., a subsidiary of FTS Group, Inc. (OTCBB:FLIP), an operator of retail wireless locations that market and sell next-generation wireless products and services and operate Wi-Fi Hot Spots, today announced that for the month of March the company will surpass its monthly wireless activation record set in February by approximately 20%. The company expects Q1 wireless activation levels to increase more than 30% from the fourth quarter.
Murray, Frank & Sailer LLP
Investor Notice: Murray, Frank & Sailer LLP has Filed a Shareholder Class Action Against Cell Therapeutics Inc. -- CTIC
NEW YORK, March 25, 2005 (PRIMEZONE) -- Murray, Frank & Sailer LLP has filed a class action lawsuit on behalf of shareholders who purchased or otherwise acquired the securities of Cell Therapeutics Inc. ("CTI" or the "Company") (Nasdaq:CTIC) between June 7, 2004 and March 4, 2005, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934. The complaint alleges that defendants' Class Period statements regarding Xyotax, one of the Company's lung cancer drugs undergoing efficacy testing, were materially false and misleading for the following reasons: (i) contrary to the defendant's repeated representations that observed results of the study were positive and encouraging, the results in fact showed that Xyotax would not meet its primary endpoint; (ii) Xyotax did not boost survival for non-small cell lung cancer any better than Taxol, a chemotherapeutic agent that had been on the market for years; (iii) based on the results of the trial the Company would not be able to begin pre launch activities and to position itself to submit a new drug application for Xyotax in the foreseeable future. The complaint further alleges that defendants were motivated to commit the fraud alleged herein so that CTI's private offering would yield more money for the Company, than if the truth was known. On December 20, 2004, CTI launched an $18.4 "Million Direct Equity Placement," selling approximately 2,586,000 shares of its common stock to institutional investors at a negotiated price per share of $7.10. In addition, during the Class Period, defendant Bianco sold 39,625 shares at artificially inflated prices for proceeds of $300,877.